Factor Model (net +0.2)
Factor Model
net +0.2 1.7 / 10Truist cuts ELV target, keeps Buy rating
Watch: Next quarterly earnings for guidance updates on member growth and Medicaid rate impacts amid regulatory scrutiny.
Truist reduced Elevance Health's price target to $375 from $390 while maintaining a Buy rating due to steady demand and stable reimbursement. Evercore ISI started coverage with an In Line rating and $345 target, citing downside risks to 2027 estimates amid policy changes. Insider activity shows heavy selling valued at over $36M, offset partially by $3.7M in insider buys, indicating mixed confidence inside the company.
Despite regulatory and policy risks flagged by Evercore, steady demand and favorable structural tailwinds support a cautiously bullish view on Elevance's healthcare services growth and financial flexibility.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when ELV changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.